Aptose Biosciences Inc. (APTO)
3.31
-0.39 (-10.54%)
At close: Mar 28, 2025, 3:57 PM
3.11
-6.04%
After-hours: Mar 28, 2025, 05:13 PM EDT
-10.54% (1D)
| Bid | 3.1 |
| Market Cap | 7.09M |
| Revenue (ttm) | 82.25K |
| Net Income (ttm) | -4.17M |
| EPS (ttm) | -87.6 |
| PE Ratio (ttm) | -0.04 |
| Forward PE | -0.09 |
| Analyst | Buy |
| Ask | 3.76 |
| Volume | 31,490 |
| Avg. Volume (20D) | 221,317 |
| Open | 3.32 |
| Previous Close | 3.70 |
| Day's Range | 3.31 - 3.38 |
| 52-Week Range | 2.39 - 51.60 |
| Beta | 1.13 |
About APTO
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and HM43239 that is in Ph...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 16, 1992
Employees 35
Stock Exchange NASDAQ
Ticker Symbol APTO
Website https://www.aptose.com
Analyst Forecast
According to 3 analyst ratings, the average rating for APTO stock is "Buy." The 12-month stock price forecast is $150, which is an increase of 4431.72% from the latest price.
Stock Forecasts1 month ago
+26.67%
Aptose shares are trading higher after a Cohort Sa...
Unlock content with
Pro Subscription
1 month ago
-22.55%
Aptose Biosciences shares are trading lower after the company announced a 1-for-30 reverse stock split.
